Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX in Adenocarcinoma of the Small Bowel and Ampulla of Vater
NCT00354887Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2004
- Primary completion
- Nov 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in small intestine adenocarcinoma (SBA), ampulla of Vater adenocarcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2004; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
small intestine adenocarcinoma (SBA)ampulla of Vater adenocarcinoma
Beyond the preview
Go deeper on NCT00354887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354887.